Karolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin
STOCKHOLM, SWEDEN – January 21, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has…
